Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Goodwill & Intangibles: 2023-2024

Historic Goodwill & Intangibles for Tarsus Pharmaceuticals (TARS) over the last 2 years, with Dec 2024 value amounting to $8.3 million.

  • Tarsus Pharmaceuticals' Goodwill & Intangibles fell 11.22% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $8.3 million for FY2024, which is 115.31% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Goodwill & Intangibles stood at $8.3 million, which was up 115.31% from $3.9 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Goodwill & Intangibles high stood at $8.3 million for FY2024, and its period low was $3.9 million during FY2023.
  • Its 2-year average for Goodwill & Intangibles is $6.1 million, with a median of $6.1 million in 2023.
  • Data for Tarsus Pharmaceuticals' Goodwill & Intangibles shows a peak YoY surged of 115.31% (in 2024) over the last 5 years.
  • Over the past 2 years, Tarsus Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $3.9 million in 2023, then surged by 115.31% to $8.3 million in 2024.